
IRLAB Therapeutics Investor Relations Material
Latest events

Q2 2025
IRLAB Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from IRLAB Therapeutics
Access all reports
IRLAB Therapeutics AB is a research and development company developing drugs for the treatment of Parkinson's disease. IRLAB develops drugs that can stop or slow down the loss of neurons in the substantia nigra, where dopamine is produced. In Parkinson's disease, loss of these neurons leads to a gradual degeneration of the motor functions. These drugs will improve symptoms without dramatically increasing the risk of side effects.
Latest articles
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
Ticker symbol
IRLAB
Country
🇸🇪 Sweden